Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

TYO: 4528

    • Home
    • TYO: 4528
Company Deals

Ono Pharmaceutical Licenses Ionis’ Sapablursen for Global Development in Polycythemia Vera

Fineline Cube Mar 12, 2025

Japan-based Ono Pharmaceutical Co., Ltd. (TYO: 4528) announced an agreement with Ionis Pharmaceuticals, Inc. to...

Company Deals

Ono Pharmaceutical Secures Deal to Acquire Deciphera Pharmaceuticals for USD 2.4 Billion

Fineline Cube May 7, 2024

Japan-based Ono Pharmaceutical Co., Ltd (TYO: 4528) has announced that it has reached an agreement...

Policy / Regulatory

China’s CDE Proposes Removal of Ambroxol Inhalation Solution and Four Other Drugs

Fineline Cube Sep 19, 2023

The Center for Drug Evaluation has issued a notification concerning the Chemical Generic Drug Reference...

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.